Ferring Announces Full Availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.
Patients with high-risk, non-muscle invasive bladder cancer now have greater access to the first and only FDA-approved intravesical gene therapy…
-
-
New Docuseries Explores the Diverse Experiences and Emotional Realities Faced by Many on the Path to Parenthood
Ferring Pharmaceuticals’ Fertility Out Loud Docuseries follows four U.S.-based couples as they face their unique fertility journeys head-on Episode one…
-
New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)
36-month follow-up data from the Phase 3 study demonstrate one-quarter of patients with high-risk, BCG-unresponsive NMIBC remained free of high-grade…
-
Ferring Praises Support From New Jersey and Minnesota as Both States Issue Proclamations Recognizing November as C. difficile Infection Awareness Month for Fourth Consecutive Year
Parsippany, NJ – November 15, 2023 – Ferring Pharmaceuticals appreciates the ongoing support from New Jersey and Minnesota as both…
-
ACG 2023 Presentations for REBYOTA® (fecal microbiota, live – jslm) Explore Association Between Gut Microbiome Composition and Health-Related Quality of Life and Evaluate Efficacy and Safety in Older Patients With Comorbidities
New analysis evaluates the association between gut microbiome composition and health-related quality of life for patients with recurrent C. diff…
-
ASRM Announces Historic $5 Million Endowment from Ferring Pharmaceuticals
“Transformational” Gift will Establish the “Ferring Endowment for the Education of Healthcare Professionals in Training” Washington, DC and Parsippany, NJ…
-
More Real-World Data and New Analyses of Data for REBYOTA® (fecal microbiota, live – jslm) Presented at IDWeek 2023
Analysis looks at early experience with REBYOTA in clinical practice Additional analyses evaluate efficacy and safety of REBYOTA in patients…
-
Ferring to Present New Data Analyses at ACG 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
Parsippany, NJ – October 3, 2023 – Ferring Pharmaceuticals today announced it will present two analyses of data for REBYOTA® (fecal…
-
Ferring Named in Fortune’s 2023 Change the World List
Fortune’s “Change the World” List recognises companies that have had a positive social impact through activities that are part of…
-
Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
Parsippany, NJ – September 21, 2023 – Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA® (fecal microbiota,…